Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to exert cardiorenal protective effects in diabetic patients and are widely used clinically. In addition, an increasing number of reports now suggest these drugs may even be beneficial in non-diabetic patients. However, SG...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Ryoichi, Miyagi, Kyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063183/
https://www.ncbi.nlm.nih.gov/pubmed/35501824
http://dx.doi.org/10.1186/s12882-022-02793-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063183/
https://www.ncbi.nlm.nih.gov/pubmed/35501824
http://dx.doi.org/10.1186/s12882-022-02793-9

Ejemplares similares